GBA mutations in Parkinson disease: earlier death but similar neuropathological features

Charles Howard Adler, T. G. Beach, H. A. Shill, John Nathaniel Caviness, Erika M Driver-Dunckley, M. N. Sabbagh, A. Patel, L. I. Sue, G. Serrano, S. A. Jacobson, K. Davis, C. M. Belden, B. N. Dugger, S. A. Paciga, A. R. Winslow, W. D. Hirst, J. G. Hentz

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background and purpose: Mutations in the glucocerebrosidase (GBA) gene are known to be a risk factor for Parkinson's disease (PD). Data on clinicopathological correlation are limited. The purpose of this study was to determine the clinicopathological findings that might distinguish PD cases with and without mutations in the GBA gene. Methods: Data from the Arizona Study of Aging and Neurodegenerative Disorders were used to identify autopsied PD cases that did or did not have a GBA gene mutation. Clinical and neuropathological data were compared. Results: Twelve PD cases had a GBA mutation and 102 did not. The GBA mutation cases died younger (76 vs. 81 years of age) but there was no difference in disease duration or clinical examination findings. No neuropathological differences were found in total or regional semi-quantitative scores for Lewy-type synucleinopathy, senile plaques, neurofibrillary tangles, white matter rarefaction or cerebral amyloid angiopathy scores. Conclusions: In longitudinally assessed, autopsied PD cases, those with GBA mutations had a younger age at death but there was no evidence for clinical or neuropathological differences compared to cases without GBA mutations. Due to the small GBA group size, small differences cannot be excluded.

Original languageEnglish (US)
Pages (from-to)1363-1368
Number of pages6
JournalEuropean Journal of Neurology
Volume24
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Glucosylceramidase
Parkinson Disease
Mutation
Cerebral Amyloid Angiopathy
Genes
Neurofibrillary Tangles
Amyloid Plaques
Neurodegenerative Diseases

Keywords

  • genetics
  • glucocerebrosidase
  • neuropathology
  • Parkinson's disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

GBA mutations in Parkinson disease : earlier death but similar neuropathological features. / Adler, Charles Howard; Beach, T. G.; Shill, H. A.; Caviness, John Nathaniel; Driver-Dunckley, Erika M; Sabbagh, M. N.; Patel, A.; Sue, L. I.; Serrano, G.; Jacobson, S. A.; Davis, K.; Belden, C. M.; Dugger, B. N.; Paciga, S. A.; Winslow, A. R.; Hirst, W. D.; Hentz, J. G.

In: European Journal of Neurology, Vol. 24, No. 11, 01.11.2017, p. 1363-1368.

Research output: Contribution to journalArticle

Adler, CH, Beach, TG, Shill, HA, Caviness, JN, Driver-Dunckley, EM, Sabbagh, MN, Patel, A, Sue, LI, Serrano, G, Jacobson, SA, Davis, K, Belden, CM, Dugger, BN, Paciga, SA, Winslow, AR, Hirst, WD & Hentz, JG 2017, 'GBA mutations in Parkinson disease: earlier death but similar neuropathological features', European Journal of Neurology, vol. 24, no. 11, pp. 1363-1368. https://doi.org/10.1111/ene.13395
Adler, Charles Howard ; Beach, T. G. ; Shill, H. A. ; Caviness, John Nathaniel ; Driver-Dunckley, Erika M ; Sabbagh, M. N. ; Patel, A. ; Sue, L. I. ; Serrano, G. ; Jacobson, S. A. ; Davis, K. ; Belden, C. M. ; Dugger, B. N. ; Paciga, S. A. ; Winslow, A. R. ; Hirst, W. D. ; Hentz, J. G. / GBA mutations in Parkinson disease : earlier death but similar neuropathological features. In: European Journal of Neurology. 2017 ; Vol. 24, No. 11. pp. 1363-1368.
@article{169d1c5fce7e445d9bc8ba4d59b69b28,
title = "GBA mutations in Parkinson disease: earlier death but similar neuropathological features",
abstract = "Background and purpose: Mutations in the glucocerebrosidase (GBA) gene are known to be a risk factor for Parkinson's disease (PD). Data on clinicopathological correlation are limited. The purpose of this study was to determine the clinicopathological findings that might distinguish PD cases with and without mutations in the GBA gene. Methods: Data from the Arizona Study of Aging and Neurodegenerative Disorders were used to identify autopsied PD cases that did or did not have a GBA gene mutation. Clinical and neuropathological data were compared. Results: Twelve PD cases had a GBA mutation and 102 did not. The GBA mutation cases died younger (76 vs. 81 years of age) but there was no difference in disease duration or clinical examination findings. No neuropathological differences were found in total or regional semi-quantitative scores for Lewy-type synucleinopathy, senile plaques, neurofibrillary tangles, white matter rarefaction or cerebral amyloid angiopathy scores. Conclusions: In longitudinally assessed, autopsied PD cases, those with GBA mutations had a younger age at death but there was no evidence for clinical or neuropathological differences compared to cases without GBA mutations. Due to the small GBA group size, small differences cannot be excluded.",
keywords = "genetics, glucocerebrosidase, neuropathology, Parkinson's disease",
author = "Adler, {Charles Howard} and Beach, {T. G.} and Shill, {H. A.} and Caviness, {John Nathaniel} and Driver-Dunckley, {Erika M} and Sabbagh, {M. N.} and A. Patel and Sue, {L. I.} and G. Serrano and Jacobson, {S. A.} and K. Davis and Belden, {C. M.} and Dugger, {B. N.} and Paciga, {S. A.} and Winslow, {A. R.} and Hirst, {W. D.} and Hentz, {J. G.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1111/ene.13395",
language = "English (US)",
volume = "24",
pages = "1363--1368",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - GBA mutations in Parkinson disease

T2 - earlier death but similar neuropathological features

AU - Adler, Charles Howard

AU - Beach, T. G.

AU - Shill, H. A.

AU - Caviness, John Nathaniel

AU - Driver-Dunckley, Erika M

AU - Sabbagh, M. N.

AU - Patel, A.

AU - Sue, L. I.

AU - Serrano, G.

AU - Jacobson, S. A.

AU - Davis, K.

AU - Belden, C. M.

AU - Dugger, B. N.

AU - Paciga, S. A.

AU - Winslow, A. R.

AU - Hirst, W. D.

AU - Hentz, J. G.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Background and purpose: Mutations in the glucocerebrosidase (GBA) gene are known to be a risk factor for Parkinson's disease (PD). Data on clinicopathological correlation are limited. The purpose of this study was to determine the clinicopathological findings that might distinguish PD cases with and without mutations in the GBA gene. Methods: Data from the Arizona Study of Aging and Neurodegenerative Disorders were used to identify autopsied PD cases that did or did not have a GBA gene mutation. Clinical and neuropathological data were compared. Results: Twelve PD cases had a GBA mutation and 102 did not. The GBA mutation cases died younger (76 vs. 81 years of age) but there was no difference in disease duration or clinical examination findings. No neuropathological differences were found in total or regional semi-quantitative scores for Lewy-type synucleinopathy, senile plaques, neurofibrillary tangles, white matter rarefaction or cerebral amyloid angiopathy scores. Conclusions: In longitudinally assessed, autopsied PD cases, those with GBA mutations had a younger age at death but there was no evidence for clinical or neuropathological differences compared to cases without GBA mutations. Due to the small GBA group size, small differences cannot be excluded.

AB - Background and purpose: Mutations in the glucocerebrosidase (GBA) gene are known to be a risk factor for Parkinson's disease (PD). Data on clinicopathological correlation are limited. The purpose of this study was to determine the clinicopathological findings that might distinguish PD cases with and without mutations in the GBA gene. Methods: Data from the Arizona Study of Aging and Neurodegenerative Disorders were used to identify autopsied PD cases that did or did not have a GBA gene mutation. Clinical and neuropathological data were compared. Results: Twelve PD cases had a GBA mutation and 102 did not. The GBA mutation cases died younger (76 vs. 81 years of age) but there was no difference in disease duration or clinical examination findings. No neuropathological differences were found in total or regional semi-quantitative scores for Lewy-type synucleinopathy, senile plaques, neurofibrillary tangles, white matter rarefaction or cerebral amyloid angiopathy scores. Conclusions: In longitudinally assessed, autopsied PD cases, those with GBA mutations had a younger age at death but there was no evidence for clinical or neuropathological differences compared to cases without GBA mutations. Due to the small GBA group size, small differences cannot be excluded.

KW - genetics

KW - glucocerebrosidase

KW - neuropathology

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=85030761938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030761938&partnerID=8YFLogxK

U2 - 10.1111/ene.13395

DO - 10.1111/ene.13395

M3 - Article

C2 - 28834018

AN - SCOPUS:85030761938

VL - 24

SP - 1363

EP - 1368

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 11

ER -